A prospective study comparing the pharmacokinetics, efficacy, and side effects of sunitinib in patients with advanced renal cell carcinoma

A prospective study comparing the pharmacokinetics, efficacy, and side effects of sunitinib in patients with advanced renal cell carcinoma - Pharmacokinetics of sunitinib in patients with advanced renal cell carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014685

Enrollment

Registered

2014-08-01

Start date

2014-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma

Interventions

Patients with advanced renal cell carcinoma are treated with sunitinib for one year.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients treated with sunitinib 2. Keeping major organ function 3. Taking agreement by document regarding participation for this clinical study

Exclusion criteria

Exclusion criteria: 1. Patients with serious illness in kidney, liver, heart, or hematogenous function 2. Disqualified by a medical doctor

Design outcomes

Primary

Measure	Time frame
Relationship between trough concentrations of sunitinib and side effects	—

Secondary

Measure	Time frame
Relationship between trough concentrations of sunitinib and efficacy	—

Countries

Japan

Contacts

Public ContactMasashi Nakayama

Osaka International Cancer Institute Department of Urology

nakayama-ma@mc.pref.osaka.jp06-6945-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026